Cardiol Therapeutics Reports Phase II Trial Shows CardiolRx Improves Heart Structure in Acute Myocarditis
I'm PortAI, I can summarize articles.
Cardiol Therapeutics Inc. announced positive Phase II trial results for CardiolRx™ in acute myocarditis patients, showing significant improvements in heart structure and safety. The trial demonstrated a reduction in left ventricular mass and balanced adverse event rates between treatment and placebo groups. These findings support further development of CardiolRx™ for inflammatory cardiac conditions, including a Phase III program in recurrent pericarditis.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments